Pfizer: Expect Another Double Beating For Q1 (Earnings Preview) (NYSE:PFE)

Group 1 - Pfizer Inc. (PFE) is experiencing significant stock decline due to the impending loss of exclusivity for its main drugs, which is influencing market perception [1] - The article highlights the potential for investors to save on equity research reports by subscribing to Beyond the Wall Investing, which provides high-quality analysis [1] - Oakoff Investments, led by a quantitative research analyst, offers insights into balancing growth and value through proprietary Wall Street information [1] Group 2 - The article does not provide any specific financial data or performance metrics related to Pfizer Inc. or the broader pharmaceutical industry [2][3]